Ollin Biosciences raises $156.2 million in Rule 506(b) equity offering
Ollin Biosciences, a Delaware biotechnology corporation, has sold $156,249,990 of a $330,000,000 private equity offering under Regulation D Rule 506(b). The first sale occurred on May 14, 2026, with 32 investors participating to date. No sales or finders compensation was paid.
Key facts
- $156,249,990 sold to date (47% of $330,000,000 target)
- 32 investors to date
- First sale date: May 14, 2026
- Rule 506(b) exemption claimed
- $173,750,010 remaining in offering
- Equity securities
Why it matters
Ollin Biosciences has closed nearly half of its $330 million private fundraising round, signaling continued capital deployment for its biotech operations.
Share
Derived from D filed 2026-06-24. Not investment advice. View the source filing on SEC.gov →